SG11201608397UA - Glyt1 inhibitors for use in the treatment of hematological disorders - Google Patents
Glyt1 inhibitors for use in the treatment of hematological disordersInfo
- Publication number
- SG11201608397UA SG11201608397UA SG11201608397UA SG11201608397UA SG11201608397UA SG 11201608397U A SG11201608397U A SG 11201608397UA SG 11201608397U A SG11201608397U A SG 11201608397UA SG 11201608397U A SG11201608397U A SG 11201608397UA SG 11201608397U A SG11201608397U A SG 11201608397UA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- hematological disorders
- glyt1 inhibitors
- glyt1
- inhibitors
- Prior art date
Links
- 208000014951 hematologic disease Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14166497 | 2014-04-30 | ||
| PCT/EP2015/059037 WO2015165842A1 (en) | 2014-04-30 | 2015-04-27 | Glyt1 inhibitors for use in the treatment of hematological disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201608397UA true SG11201608397UA (en) | 2016-11-29 |
Family
ID=50677958
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201608397UA SG11201608397UA (en) | 2014-04-30 | 2015-04-27 | Glyt1 inhibitors for use in the treatment of hematological disorders |
| SG10201909382U SG10201909382UA (en) | 2014-04-30 | 2015-04-27 | Glyt1 inhibitors for use in the treatment of hematological disorders |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201909382U SG10201909382UA (en) | 2014-04-30 | 2015-04-27 | Glyt1 inhibitors for use in the treatment of hematological disorders |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9877963B2 (en) |
| EP (1) | EP3137073B1 (en) |
| JP (1) | JP6283766B2 (en) |
| KR (1) | KR101869185B1 (en) |
| CN (1) | CN106163520B (en) |
| AR (1) | AR100209A1 (en) |
| CY (1) | CY1120508T1 (en) |
| ES (1) | ES2683184T3 (en) |
| HR (1) | HRP20181205T1 (en) |
| MA (1) | MA39927B1 (en) |
| MY (1) | MY189930A (en) |
| PH (1) | PH12016501784A1 (en) |
| PT (1) | PT3137073T (en) |
| RS (1) | RS57535B1 (en) |
| SG (2) | SG11201608397UA (en) |
| SI (1) | SI3137073T1 (en) |
| TR (1) | TR201809598T4 (en) |
| WO (1) | WO2015165842A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3199156A1 (en) * | 2016-02-01 | 2017-08-02 | Heinrich-Heine-Universität Düsseldorf | Use of glycine transporter 1 antagonists as central nervous analgesics |
| CU20200106A7 (en) * | 2018-06-20 | 2021-08-06 | Axcella Health Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES AND THALASEMIAS |
| WO2021142329A1 (en) * | 2020-01-09 | 2021-07-15 | Disc Medicine, Inc. | Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors |
| KR20230169982A (en) * | 2021-03-12 | 2023-12-18 | 디스크 메디슨, 인크. | Compositions and methods for treating anemia associated with ribosomal disorders |
| CA3220137A1 (en) * | 2021-05-14 | 2022-11-17 | Disc Medicine, Inc. | Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors |
| AU2022283357A1 (en) * | 2021-05-27 | 2023-12-07 | Disc Medicine, Inc. | Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with a solid form of bitopertin |
| WO2023235326A1 (en) * | 2022-05-31 | 2023-12-07 | Disc Medicine, Inc. | Compositions and methods for treating hepatic porphyrias with glycine transport inhibitors |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4252598B2 (en) * | 2003-08-11 | 2009-04-08 | エフ．ホフマン−ラ ロシュ アーゲー | Piperazine having an OR-substituted phenyl group and their use as a GLYT1 inhibitor |
| KR100928599B1 (en) * | 2005-02-07 | 2009-11-26 | 에프. 호프만-라 로슈 아게 | Heterocyclic Substituted Phenyl Methanone as Inhibitor of Glycine Transporter 1 |
-
2015
- 2015-04-27 TR TR2018/09598T patent/TR201809598T4/en unknown
- 2015-04-27 PT PT157179169T patent/PT3137073T/en unknown
- 2015-04-27 MY MYPI2016001545A patent/MY189930A/en unknown
- 2015-04-27 ES ES15717916.9T patent/ES2683184T3/en active Active
- 2015-04-27 RS RS20180897A patent/RS57535B1/en unknown
- 2015-04-27 SG SG11201608397UA patent/SG11201608397UA/en unknown
- 2015-04-27 MA MA39927A patent/MA39927B1/en unknown
- 2015-04-27 KR KR1020167030222A patent/KR101869185B1/en active IP Right Grant
- 2015-04-27 EP EP15717916.9A patent/EP3137073B1/en active Active
- 2015-04-27 JP JP2017505724A patent/JP6283766B2/en active Active
- 2015-04-27 SI SI201530334T patent/SI3137073T1/en unknown
- 2015-04-27 SG SG10201909382U patent/SG10201909382UA/en unknown
- 2015-04-27 CN CN201580016721.4A patent/CN106163520B/en active Active
- 2015-04-27 WO PCT/EP2015/059037 patent/WO2015165842A1/en active Application Filing
- 2015-04-28 AR ARP150101268A patent/AR100209A1/en unknown
-
2016
- 2016-09-13 PH PH12016501784A patent/PH12016501784A1/en unknown
- 2016-10-26 US US15/334,722 patent/US9877963B2/en active Active
-
2018
- 2018-07-25 HR HRP20181205TT patent/HRP20181205T1/en unknown
- 2018-08-06 CY CY20181100809T patent/CY1120508T1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN106163520B (en) | 2019-12-13 |
| TR201809598T4 (en) | 2018-07-23 |
| WO2015165842A1 (en) | 2015-11-05 |
| US20170042888A1 (en) | 2017-02-16 |
| MA39927A (en) | 2017-03-08 |
| RS57535B1 (en) | 2018-10-31 |
| MA39927B1 (en) | 2018-09-28 |
| MY189930A (en) | 2022-03-22 |
| HRP20181205T1 (en) | 2018-09-21 |
| EP3137073B1 (en) | 2018-06-06 |
| SG10201909382UA (en) | 2019-11-28 |
| JP6283766B2 (en) | 2018-02-21 |
| EP3137073A1 (en) | 2017-03-08 |
| PH12016501784B1 (en) | 2016-11-07 |
| CY1120508T1 (en) | 2019-07-10 |
| JP2017511385A (en) | 2017-04-20 |
| CN106163520A (en) | 2016-11-23 |
| US9877963B2 (en) | 2018-01-30 |
| SI3137073T1 (en) | 2018-09-28 |
| PT3137073T (en) | 2018-07-27 |
| ES2683184T3 (en) | 2018-09-25 |
| PH12016501784A1 (en) | 2016-11-07 |
| AR100209A1 (en) | 2016-09-21 |
| KR20160130517A (en) | 2016-11-11 |
| KR101869185B1 (en) | 2018-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL247841A0 (en) | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders | |
| HK1243325A1 (en) | Compositions and methods to treat vision disorders | |
| ZA201707303B (en) | Compositions and methods for the treatment of immunodeficiency | |
| PL3811943T3 (en) | Compound for use in the treatment of ocular disorders | |
| HRP20181205T1 (en) | Glyt1 inhibitors for use in the treatment of hematological disorders | |
| IL247589A0 (en) | Dihydropyridinone mgat2 inhibitors for use in the treatment of metabolic disorders | |
| IL247699A0 (en) | Compositions and methods for treating kidney disorders | |
| IL251904B (en) | Apilimod for use in the treatment of melanoma | |
| PL3122349T3 (en) | Compositions for the treatment of autodigestion | |
| IL263804A (en) | Wnt inhibitors for use in the treatment of fibrosis | |
| HK1220374A1 (en) | Compositions and methods for the treatment of carboxyhemoglobinemia | |
| HUE039750T2 (en) | 6-hydroxybuspirone for use in the treatment of movement disorders | |
| HUE046190T2 (en) | Gata-3 inhibitors for use in the treatment of th2-driven asthma | |
| IL251345A0 (en) | Compositions for use in the treatment of peri-implantitis | |
| IL246855A0 (en) | Agents for use in the treatment of retinal inflammation | |
| HK1225994A1 (en) | Compositions for use in the treatment of allergic conditions | |
| IL251840A0 (en) | Use of pemirolast in the treatment of acute asthma | |
| IL248494A0 (en) | Methods and compositions for treatment of lipid storage disorders | |
| EP3200795A4 (en) | Use of agents for treating fat-related disorders | |
| ZA201408464B (en) | Composition for the use in treatment of asthma |